Drugs / MT-0169
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06522373 | Oct 2024 | leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT04017130 | Feb 2020 → Dec 2023 | refractory plasma cell neoplasm | Molecular Templates, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-0169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06522373 ↗ |
| Action | Deplete | “It delivers a dose of a modified toxin that kills these cells.” NCT04017130 ↗ |
| Modality | Protein / enzyme biologic | “MT-0169 (an Engineered toxin body (ETB)” NCT04017130 ↗ |
| Route | Intravenous | “MT-0169 will be given as an intravenous (IV) infusion over 60 minutes” NCT04017130 ↗ |
| Target | CD38 | “MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma cancer cells.” NCT04017130 ↗ |